These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 23513419)

  • 21. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New Developments in CKD-MBD. Development and progression of CKD-MBD in predialysis period -when and how?].
    Komaba H
    Clin Calcium; 2014 Dec; 24(12):1771-8. PubMed ID: 25423921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
    Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
    Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chronic kidney disease and nutrition].
    Yoshida T; Kumagai H
    Clin Calcium; 2016 Mar; 26(3):369-74. PubMed ID: 26923973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CKD-mineral and bone disorder management in kidney transplant recipients.
    Alshayeb HM; Josephson MA; Sprague SM
    Am J Kidney Dis; 2013 Feb; 61(2):310-25. PubMed ID: 23102732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults.
    Bellorin-Font E; Ambrosoni P; Carlini RG; Carvalho AB; Correa-Rotter R; Cueto-Manzano A; Jara A; Jorgetti V; Negri AL; Olaizola I; Salusky I; Slatopolsky E; Weisinger JR; ;
    Nefrologia; 2013; 33 Suppl 1():1-28. PubMed ID: 23629678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Kidney and bone update : the 5-year history and future of CKD-MBD. Bisphosphonates treatment for chronic kidney disease-mineral and bone disorder].
    Mori H; Okada Y; Tanaka Y; Hashimoto O
    Clin Calcium; 2012 Jul; 22(7):1034-42. PubMed ID: 22750936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The future of phosphate binders: a perspective on novel therapeutics.
    Cernaro V; Santoro D; Lucisano S; Nicocia G; Lacquaniti A; Buemi M
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1459-63. PubMed ID: 25243756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Kidney and bone update : the 5-year history and future of CKD-MBD. Mineral and bone disorder in kidney transplant recipients].
    Fujii N; Okuno A; Yonemoto S; Nishimura K; Kishikawa H; Ichikawa Y
    Clin Calcium; 2012 Jul; 22(7):1050-8. PubMed ID: 22750938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [CKD-MBD as a predictor of mortality].
    Hamano T
    Nihon Jinzo Gakkai Shi; 2014; 56(8):1233-42. PubMed ID: 25551984
    [No Abstract]   [Full Text] [Related]  

  • 32. [Current approaches in the treatment of hyperphosphatemia in chronic kidney disease].
    Matuszkiewicz-Rowińska J; Kościelska M
    Wiad Lek; 2017; 70(6 pt 2):1161-1165. PubMed ID: 29533905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?
    Cozzolino M; Ureña-Torres P; Vervloet MG; Brandenburg V; Bover J; Goldsmith D; Larsson TE; Massy ZA; Mazzaferro S;
    Nephrol Dial Transplant; 2014 Oct; 29(10):1815-20. PubMed ID: 24516228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic kidney disease-mineral bone disorder: an update on the pathology and cranial manifestations.
    Raubenheimer EJ; Noffke CE; Hendrik HD
    J Oral Pathol Med; 2015 Apr; 44(4):239-43. PubMed ID: 24646006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of hyperphosphatemia-mediated vascular calcification in cardiovascular outcomes and its management: a review.
    Latif F; Khalid MM; Khan F; Omar Z; Ali FA
    J Cardiovasc Med (Hagerstown); 2013 Jun; 14(6):410-5. PubMed ID: 23392553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mineral and bone disorders in chronic kidney disease: new insights into mechanism and management.
    Lewis R
    Ann Clin Biochem; 2012 Sep; 49(Pt 5):432-40. PubMed ID: 22807503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease.
    Lundquist AL; Nigwekar SU
    Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):120-6. PubMed ID: 26785065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New Developments in CKD-MBD. Molecular mechanisms of intestinal and renal phosphate transport].
    Segawa H; Ikuta K; Miyamoto K
    Clin Calcium; 2014 Dec; 24(12):1793-9. PubMed ID: 25423924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone alkaline phosphatase in CKD-mineral bone disorder.
    Sardiwal S; Magnusson P; Goldsmith DJ; Lamb EJ
    Am J Kidney Dis; 2013 Oct; 62(4):810-22. PubMed ID: 23623575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).
    Uhlig K; Berns JS; Kestenbaum B; Kumar R; Leonard MB; Martin KJ; Sprague SM; Goldfarb S
    Am J Kidney Dis; 2010 May; 55(5):773-99. PubMed ID: 20363541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.